Key points are not available for this paper at this time.
Findings reinforce results from our previous study that CAB provides dramatic clinical improvements with an excellent safety profile. The CAB should, therefore, be considered as the primary therapy for giant prolactinomas.
Almalki et al. (Wed,) studied this question.